Autologous stem cell transplantation (ASCT) is an important treatment modality in light chain (AL) amyloidosis. Use of reduced-dose melphalan conditioning is common, given the associated organ and functional decline. The impact of full-intensity melphalan conditioning (n = 314) was compared to reduced-dose conditioning (n = 143). Patients in the full-intensity group were younger, with better performance status, fewer involved organs, lower tumor burden and lower Mayo stage. Full-dose conditioning was associated with higher rate of very good partial response or better (79% vs 62%; P o 0.001), complete response rate (53% vs 37%; P = 0.003) and organ response rate (74% vs 59%; P = 0.002) as compared to reduced-dose conditioning. PFS was superior in the full-intensity group compared to the reduced-dose group (4-year PFS 55% vs 31%; P o 0.001) as well as a longer overall survival (OS) 4-year OS (86% vs 54%; P o 0.001). In addition, the OS and PFS were significantly lower in the reduced-dose group compared to the full-intensity group in Mayo stage III/IV as well as stage I/II. A multivariate analysis confirmed an independent impact for conditioning dose on PFS/OS. This study calls for re-assessment of the use of reduced-dose conditioning in ASCT for AL amyloidosis.
INTRODUCTION
The introduction of autologous stem cell transplantation (ASCT) for light chain (AL) amyloidosis more than 20 years ago 1,2 has markedly changed the disease course for those patients who are eligible for this intensive approach, demonstrating high response rates and prolonged survival. [3] [4] [5] [6] [7] The previous lack of effective standard therapies led to application of reduced-dose conditioning to allow less fit patients to safely proceed with ASCT. However, the rationale of reduced dosing of melphalan in a more fragile population was assessed more than a decade ago in two studies, both showing a lower response [7] [8] [9] and reduced survival. 7, 9 However, to date it is unclear whether the poorer outcomes seen with reduced-dose melphalan is a result of the underlying characteristics of the target population (frailty, advanced cardiac infiltration) or whether the melphalan dose has a role in these inferior outcomes.
MATERIALS AND METHODS
Four hundred and fifty-seven (n = 457) consecutive patients newly diagnosed with AL amyloidosis who underwent ASCT as their first-line treatment between 1 January 2000 and 31 August 2015 were included in the study. Patients who received pre-ASCT induction treatment were included, unless they had evidence for progression before ASCT. Patients with AL amyloidosis due to a lymphoproliferative disorder were excluded. All patients had provided informed consent for the use of their medical records. The Mayo Clinic Institutional Review Board approved this study. Data were extracted from a prospectively maintained database and all patients' charts were reviewed to assure data completeness and accuracy.
Organ involvement was defined according to consensus criteria. 10 The 2004 Mayo and 2012 revised Mayo staging systems were used for risk stratification. 11, 12 Response was assessed in accordance with the consensus criteria and progression included both hematological (50% increase in serum M protein (to 40.5 g/dL) or urine M protein (to 4200 mg/day) or free light chains (to 4100 mg/dL)) and/or organ progression. 13 Performance status was assessed at transplant using the Karnofsky score.
14 Full-intensity melphalan (200 mg/m 2 ) or reduced-dose melphalan (o 180 mg/m 2 ; 86% received melphalan 140 mg/m 2 ) were used as the two comparator groups in the study. Of the 457 patients, 314 (69%) received full-intensity therapy, whereas 143 patients (31%) received reduced-intensity therapy. The conditioning dose was adjusted depending on patient performance status, comorbidities and renal insufficiency (serum creatinine ⩾ 2 mg/dL). 15 Patients were evaluated on day 100 post transplant for response, which included serum and urine studies and bone marrow examination. Response was available for 426 patients (93% of the study population). FISH was available for 241 patients (53% of patients).
Statistical analysis
Data were reported as the median and interquartile range. The χ2 and the Fisher exact tests were used to compare categorical variables, and the Wilcoxon signed rank test was used for continuous variables.
PFS and overall survival (OS) were calculated using the Kaplan-Meier method; PFS (available for 443 patients; 97% of patients) was defined as time from ASCT to progression (hematological and/or organ) or death, whichever came first; OS was defined as time from ASCT to death from any cause. Survival differences between groups were calculated with the logrank test. To eliminate the effect of early death, we performed a landmark analysis for PFS and OS at 6 months from ASCT. Cox proportional hazards model was used to assess predictors for PFS and OS. The variables 
RESULTS

Baseline characteristics and details of transplant
The baseline characteristics of the study population stratified by the conditioning dose groups are presented in Table 1 (clinical)  and Table 2 (laboratory). Patients in the full-intensity group were younger, had a higher proportion with Karnofsky score ⩾ 80, had lower plasma cell tumor burden, less multiorgan and cardiac involvement and had a higher percentage of patients in lower Mayo stages as compared with patients in the reduced-intensity group. Only 6% of the patients had serum creatinine ⩾ 2 mg/dL, a fraction that was higher in the reduced-intensity group compared to the full-intensity group (15% vs 2%; P o0.001).
Changes in the use of conditioning intensity were observed over time. Of the 226 ASCTs performed in the years 2008-2015, 180 procedures (80%) used full-intensity conditioning, whereas only 134/231 procedures (58%) performed in the years 2000-2007 were full-intensity (P o0.001). No difference was seen in the age distribution between these periods (P = 0.22), but more patients had single-organ involvement in the 2008-2015 period compared to the 2000-2007 period (54% vs 39%; P = 0.001).
The details of the induction chemotherapy pre-transplant (if received), stem cell collection, marrow engraftment, hospitalization and early death (within 100 days) post transplant are listed in Table 3 .
Hematological and organ response following ASCT The rate of very good partial response (VGPR) or better was significantly higher in the full-intensity group compared to the Abbreviations: BMPC = bone marrow plasma cell; dFLC = difference between involved and uninvolved light chains; eGFR = estimated glomerular filtration rate; IQR = interquartile range; NT-proBNP = N-terminal pro b-type natriuretic peptide. Bold indicates statistical significance at Po0.05.
reduced-intensity group (79% vs 62%; P o 0.001). This difference was mainly due to a higher complete response (CR) rate (53% vs 37%; P = 0.003). The percentage of non-responders (attainment of less than partial response) was less in the full-intensity group compared to the reduced-intensity group (5% vs 16%; P o0.001).
The rate of organ response was higher in the full-intensity group compared to the reduced-intensity group (74% vs 59%; P = 0.002). This difference between groups was seen among those with single-organ involvement (76% vs 57%; P = 0.02) and among those with two or more involved organs (73% vs 60%; P = 0.04).
Survival PFS was significantly longer in the full-intensity group compared to the reduced-intensity group (4-year PFS 55% vs 31%, P o 0.001; Figure 1a ). The PFS advantage of full-intensity melphalan remained significant in subgroup analysis based on achievement of ⩾ VGPR (4-year PFS 69% vs 51%, P = 0.01; Figure 1b ) as well as oVGPR (4-year PFS 10% vs 5%, P = 0.01; Figure 1c) . In a landmark analysis at 6 months from transplant, PFS was longer in the full-dose melphalan group compared to reduced-dose melphalan (4-year PFS 62% vs 43%, P = 0.002; Figure 1d ). Similarly, OS was significantly longer in the full-intensity group compared to the reduced-intensity group (4-year OS 86% vs 54%, P o 0.001; Figure 2a ). The superior OS in the full-intensity group remained significant in the subgroup of patients with ⩾ VGPR (4-year OS 94% vs 83%, P o 0.001; Figure 2b ) and those with o VGPR 4-year OS 69% vs 22%, Po 0.001; Figure 2c) . In a landmark analysis at 6 months from transplant, OS was significantly longer in the full-dose melphalan group compared to the reduced-dose group (4-year OS 91% vs 63%, P o 0.001; Figure 2d ).
We also evaluated the impact on PFS and OS in the full-intensity group as compared to the reduced-intensity group according to the lower (stages I and II) vs higher (stages III and IV) 2012 Mayo Stages. The PFS was longer in the full-intensity group as compared to the reduced-dose group in lower (4 year PFS, 55% vs 35%; Number of patients who died with 100 days following ASCT, N (%) 5 (2%) 9 (6%) 0.01
Abbreviations: ASCT = autologous stem cell transplant; IQR = interquartile range. Bold indicates statistical significance at Po 0.05. Probability of survival without progression (Figures 3a and b) . Similarly, the OS was also higher for the full-intensity vs reduced-dose group in lower (4 year OS, 89% vs 65%; P o 0.001) and higher (4 year OS, 69% vs 34%; P = 0.02) Mayo stages (Figures 3c and d) . The impact of various variables on PFS and OS in subgroups of patients who did and did not receive induction prior to ASCT are shown in Supplementary Tables 1 and 2 , respectively. In addition, in light of the independent effect of gender on PFS/OS, we assessed the rate of ⩾ VGPR between the two conditioning-dose groups stratified by gender. Among men, the rate of ⩾ VGPR was higher in the full intensity as compared to the reduced-dose group (75% vs 51%; P o0.001), while it was similar in women (84% vs 80%; P = 0.6).
t (11;14) and its effect on response and survival by conditioning dose: subgroup analysis Among patients with t(11;14) (n = 131), those who received full-dose conditioning achieved ⩾ VGPR more frequently compared to those who received reduced-dose melphalan (75% vs 51%; P = 0.01). This differential rate of ⩾ VGPR did not reach statistical significance for those patients without t(11;14) (n = 110; 80% vs 68%; P = 0.21). However, this did not translate into differential OS rates. Patients with or without t(11;14) had superior OS when full-dose conditioning was employed compared to reduced-dose conditioning (t(11;14)-positive patients, 4-year OS 91% vs 54%; t(11;14)-negative patients, 4-year OS 92% vs 60%, Po 0.001 for both comparisons).
DISCUSSION
With the changing treatment landscape of AL amyloidosis, the question of whether to offer ASCT as first-line treatment becomes very pertinent, especially in those in whom full-dose conditioning is considered to be unsafe. Reduced-dose conditioning is often utilized in an attempt to reduce therapy-related morbidity and mortality and allow more patients to be eligible for transplant, although this may compromise the response rates and survival duration. [7] [8] [9] In this study we assessed the conditioning dose in a large cohort of newly diagnosed AL amyloidosis patients and report a lower response rate (hematological and organ) and a shorter survival associated with reduced-dose conditioning. Reduced-dose conditioning has an independent impact on Abbreviations: BMPC = bone marrow plasma cell; dFLC = difference between involved and uninvolved light chains; eGFR = estimated glomerular filtration rate; NS = nonsignificant; OS = overall survival; RR = risk ratio. Bold indicates statistical significance at Po 0.05. Abbreviations: BMPC = bone marrow plasma cell; dFLC = difference between involved and uninvolved light chains; eGFR = estimated glomerular filtration rate; NS = nonsignificant; OS = overall survival; RR = risk ratio. Bold indicates statistical significance at Po 0.05.
Conditioning dose in AL amyloidosis N Tandon et al survival, even after factors reflecting adverse disease characteristics were taken into consideration. Hence, the poorer outcomes in such patients not only resulted from the patient characteristics leading to dose reduction, but also emphasize the effect of dose attenuation. The increase in the availability of effective therapies for AL amyloidosis may help in the decision to omit the use of attenuated conditioning in this disease and rather choosing standard treatments. This approach was seen in our practice in recent years, as demonstrated in this study by a relative increase in the use of full-dose melphalan from 58% in the 2000-2007 period to 80% in the 2008-2015 period. However, data from the CIBMTR rather suggest an increased reliance on reduced-dose melphalan conditioning in recent years. 8 In fact, the use of reduced-dose melphalan was more common than full-dose melphalan. This approach should be re-assessed in the current era, in light of our results, as well as prior results (including the CIBMTR study, showing an increased risk of progression with reduced-dose conditioning).
FISH data are emerging as an important tool in therapeutic decision-making in AL amyloidosis. [16] [17] [18] Therefore, with inferior response and survival among patients harboring t (11;14) , ASCT remains the main therapeutic modality. However, subgroup analysis of patients with t (11; 14) in this study revealed that deep response, PFS and OS were all inferior in the reduced-dose conditioning group compared to patients who received fullintensity conditioning. We have demonstrated in prior study that t(11;14) is associated with poor survival in bortezomib-treated patients only among patients with favorable disease features. 18 Altogether, our data suggest that in patients with t(11;14) and favorable features, full-intensity conditioning should be strongly considered.
One of the emerging findings from this study is the impact of gender on response and survival in ASCT patients. Male patients had an inferior deep response (⩾ VGPR) with reduced-dose melphalan compared to full-intensity conditioning, and male gender was an independent predictor for adverse PFS and OS. A similar observation was recently reported by our group. 19 There are very limited data on outcome by gender in ASCT in the various plasma cell disorders. A superior PFS in ASCT in myeloma female patients was reported. 20 In addition, one study in AL amyloidosis showed superior OS with standard-dose melphalan for women. 21 Studies on melphalan metabolism are also rare. A study on melphalan pharmacokinetic in various malignancies showed a higher melphalan clearance in men than in women. 22 Women also were reported to experience more oral mucositis with high-dose melphalan. 23 Research attention should be brought forward in light of these findings and as gender-personalized medicine is an emerging clinical tool. 24 The limitations of this study include the retrospective design, lack of complete data on all patients, which is explained by the nature of our center as a referral center, as some of the work-up done elsewhere and is not repeated at all times upon arrival.
In summary, this study demonstrated that AL amyloidosis patients treated with ASCT in first line have inferior response and shorter survival with the use of reduced-dose melphalan. Reduced-dose conditioning retained significance in prediction of poorer survival even after taking factors leading to dose reduction into account. This study has meaningful impact, considering the growing use of attenuated-dose melphalan in AL amyloidosis.
